Mink Therapeutics Inc(INKT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $11.27 (+2.45%), 시가총액 $0.05B, 52주 범위 $6.89 ~ $64.17.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with an
Mink Therapeutics Inc의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
Mink Therapeutics Inc의 현재 주가는 $11.27 (+2.45%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
Mink Therapeutics Inc의 시가총액은 약 $0.05B입니다.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural kille